ABOUT 14th_ELSF
> REGISTRATION
> AGENDA​
> ATTENDEES​
> INVESTORS​
> PRESENTERS​
> SPONSORS​
> SUPPORTERS​
> NETWORKING

> ABOUT LAST YEAR​

We are pleased to announce the 14th Annual European Life Sciences CEO Forum, which will take place on the 10th - 12th of March 2021 and be part of the Digital Sachs Spring Life Sciences Week, that will also incorporate the 2nd Annual European HealthTech CEO Forum.

Due to the pandemic we have decided that for the first time Sachs Zurich events will be held in a digital format. This will allow us to support our community and past attendees. We will provide both the usual stimulating programme and the networking opportunities through the audio/video online meeting system.

Back for its 14th Annual Edition, this global bio-pharma industry event will address through its programme the main challenges for 2021 in investment, partnering and alliance management. Key players contribute their insights in panels which cover the macro picture as well as innovation in different therapeutic sectors.

The main programme for the 14th Annual ELSF is spread throughout 2 days (10th-11th of March) and will include BioCapital & Investment Day and Bio-Pharma Partnering & Therapeutics Day. The two days will feature more than 14 hours of high-level speeches, panel discussions and spotlight showcases by leading industry corporates. In addition, there is a global company showcase of 50+ presentations by established public, private, emerging and seed companies, offering innovative solutions and seeking investment and partnering opportunities. We anticipate 400+ delegates will register for the forum from all Life Sciences sectors, with the target audience being corporate and financial investors/partners, bankers and advisors.

Meetings will take place from the 8th to 12th of March. Moreover, the system will be open for 12 hours a day and we expect 1500+ meetings completed over 5 days. The conference will be held in the Central European Time Zone. The digital event will consist of:

BioCapital & Investment Day (Wednesday, 10th of March)

• State of the Industry Panel
• China Partnering & Investment Panel
• European Equities Investment Panel
  
• Accessing US Capital Markets Panel
  
• VC, Private Equity & Crossover Funds Panel
• Early Stage Innovation & Investment Panel
  

Bio-Pharma Partnering & Therapeutics Day (Thursday, 11th of March)

• Pharma M&A and Partnering Panel
• Immuno-Oncology Partnering Panel
• Advances in Immuno-Oncology Panel
• Platform Technologies & Novel Therapeutics Panel
• Genetic Medicine & New Modalities Panel
• Progress in Alzheimer’s, Dementia & Diagnostics Panel

Networking Day (Friday, 12th of March)

Confirmed Keynote Speakers Include:

• Kurt Höller, Director of Business Creation, EIT Health e.V.*
• Big Pharma Fireside Chat with Nigel Sheail, Global Head of M&A and BD&L, Novartis International AG, moderated by Je­ffrey Bockman, EVP, Head of Oncology Practice, Cello Health BioConsulting.
• Introductory Speech by Sandra Ferri, Head of Life Sciences, European Investment Fund
• Keynote: “How China is Transforming the Clinical Development Landscape & the Biopharma Industry”​ By John Oyler, Co-Founder, Chairman & CEO, BeiGene Ltd.

Confirmed Speakers Include:

• Adam Kostyál, SVP of the Global Listing Services & Head of European Listings, Nasdaq
• Andreas Hohn, Director of Transaction Excellence, Roche Partnering, F. Hoffmann-La Roche Ltd.
• Anker Lundemose, CEO, Mission Therapeutics Ltd
• Aram Mangasarian, CEO, NOXXON Pharma NV
• Ashish Patel, Principal, Optum Ventures
• Bibhash  Mukhopadhyay, Principal, New Enterprise Associates (NEA)
• Carlos de Sousa, CEO, Ultimovacs ASA
• Carlos Buesa, Founder & CEO, Oryzon Genomics S.A.
• Chris Maggos, Managing Director, Head of Europe, LifeSci Advisors
• Christophe Bourrilly, Head of Healthcare, Oddo BHF  co-chair for European Capital Markets Panel
• Corinne Venot, Senior Director, Business Development, BeiGene Ltd.
• Dennis Purcell, Founder, Aisling Capital LLC
• Duncan Young, Director, Search & Evaluation, Oncology R&D, AstraZeneca
• Ed Zhang, Venture Partner, Hillhouse Capital
• Eric Halioua, President & CEO, PDC*line Pharma SA
• Erik Manting, CBO, Immunicum AB
  
• Esteban Pombo-Villar, CEO, TargImmune Therapeutics AG
• Fabian Buller, CBO, Neurimmune AG
• Fintan Walton, Founder & CEO, PharmaVentures Ltd.
• Gil Bar-Nahum, Managing Director, EMEA Head of Biotechnology, Jefferies International Ltd.
• Guillaume Vignon, SVP, Business Development, BeiGene Ltd.
• Hans Schambye, CEO, Galecto, Inc.
• Heinz Lubenau, Co-Founder & CEO, VAXIMM
• Helen Chen, Greater China Managing Partner & Head of China Life Sciences, L.E.K. Consulting
• Hubert Birner, Managing Partner, TVM Life Science Management GmbH
• Ioannis Sapountzis, Corp. SVP, Global Head of BD&L, Boehringer Ingelheim International GmbH
• Jay Olson, Managing Director & Senior Analyst, Oppenheimer & Co. Inc.
• Jeffrey Bockman, EVP, Head of Oncology Practice, Cello Health BioConsulting
• Jennifer Laird, Vice President, Search & Evaluation – Neuroscience, Eli Lilly and Company
• Jesús Martin-Garcia, CEO, GeNeuro S
• Jo Pisani, Strategic Advisor, Non Executive Director & Charity Trustee, UK Dementia Research Institute
• John Baker, SVP, Product Portfolio & Innovation, Abcam PLC
• John Chin, Chief Business Officer, Antengene Biotech
• Jonathan Wang, SVP, Head of Business Development, Zai Lab Ltd.
• Katya  Smirnyagina, Executive Director, Capricorn Partners NV
• Khatereh Ahmadi, Executive Director, Oncology Search & Evaluation Lead for Europe, MSD
• Lior Teitelbaum, CBO, FutuRx Ltd.
• Lynn Durham, Founder, CEO, STALICLA S.A.
• Matthew Stork, CEO, Cambridge Cognition Ltd.
• Matthias Müllenbeck, SVP, Head Global BD & Alliance Management, Merck KGaA
• Melissa McCracken, Principal, Nextech Invest Ltd.
• Michael Altorfer, CEO, Swiss Biotech Association
• Michael Margolis, Managing Director, Co-Head Healthcare & Head of Life Sciences, Oppenheimer & Co. Inc.
• Michael Mulqueen, VP Business Development, eTheRNA immunotherapies NV
• Michael Rice, Founding Partner, LifeSci Advisors
• Michael Rice, Principal, Head of Advanced Therapeutics, Cello Health BioConsulting
• Mike Romanos, Co-Founder & CEO, Microbiotica Ltd.
• Nathalie ter Wengel, European Lead, Worldwide Business Development, Pfizer, Inc.
• Naveed Siddiqi, Senior Partner, Novo Holdings A/S
• Nigel Sheail, Global Head of M&A and BD&L, Novartis International AG
• Olav Zilian, Senior Healthcare Analyst, VP, Mirabaud Securities Ltd.
• Otello Stampacchia, Managing Director, Omega Fund Management (US), Inc.
• Patrick Benz, Sr. Director Alliance Management, The Janssen Pharmaceutical Companies of Johnson & Johnson
• Paul Hermant, Partner, Bird & Bird LLP
• Philippe Verwaerde, CEO, AlzProtect
• Pierre-Jean Wip­, Innovation Advisor, Innovaud
• Priyanka Belawat, Investment Advisor Private Equity, HBM Partners AG
• Rainer Strohmenger, Managing Partner, Wellington Partners
• Reagan Jarvis, Co-Founder & CEO, Anocca AB
• Richard Godfrey, CEO, BerGenBio ASA
• Sascha Bucher, Founder, Forty51 Ventures
• Sam Fazeli, Head of Research, Senior Pharmaceuticals Analyst, Bloomberg Intelligence
• Sander van Deventer, Operating Partner, Forbion
• Sandra Ferri, Head of Life Sciences, European Investment Fund*
• Sébastien Petitet, Chief Business Development Officer, Brenus Pharma
• Sofia Ioannidou, Partner, Andera Partners
• Søren Møller, Managing Partner, Novo Seeds, Novo Holdings A/S
• Stephanie Léouzon, Partner & Head of Europe, Torreya Partners LLP
• Sumant  Kulkarni, Managing Director, Biotechnology Equity Research, Canaccord Genuity LLC
• Ted Fjällman, CEO, Prokarium Ltd.
• Thibaut Roulon, Senior Investment Director, Bpifrance
• Tim Haines, Chairman & Managing Partner, Abingworth
• Tomas Landh, Innovation Sourcing VP, Senior Principal Scientist R&D Global Search & Evaluation, Novo Nordisk A/S
• Wesley Holmes, Partner, Latham & Watkins LLP
• Yochi Slonim, Co-Founder & CEO, Anima Biotech, Inc.
• Zhihong Chen, President & CEO, Curon Biopharmaceutical
• More TBA...

---

SPOTLIGHT PRESENTERS:

PRESENTING COMPANIES:

---

PARTICIPATION OPTIONS:

Free access to view live sessions is provided to all interested and qualified participants. This will allow us to increase the size of the audience and provide a higher exposure for participating companies. Additionally, you can purchase a Video on Demand pass, which will allow you to view not only live sessions, but also recordings of all sessions, in addition to speaker and company profiles and their presentations.
 
The Online Meeting System will open on the 22nd of February for uploading profiles and sending meeting invites. Meetings will take place from the 8th to 12th of March. System will allow you to have a secure audio/video call, as well as option to present slides using screen share function. Meetings will last for 30 minutes. Basic Online Meeting System Access with 10 meeting invitations will be provided complimentary for qualified institutional (buy/sell-side), private equity and venture investors. The number of passes is limited, and priority is given to regular participants, however organizer has the discretion to reject passes. Other participants may consider purchasing Basic, Advanced and Premium Access with an option for a live spotlight or a pre-recorded showcase presentation. The number of meeting invites defines how many requests can be sent. If meeting invite is declined, you will receive an invite credit back that can be reused. The number of invites does not restrict how many meeting invitations you can receive.

PRESENTING OPPORTUNITIES:

Gain additional exposure to high-level decision makers by presenting at the forum, which offers excellent opportunities to showcase your company’s investment and partnering offering. This typically include technology and financial highlights. This adds to the news flow from the forum and generates greater interest in meetings from other delegates.
 
​For those interested to join the companies’ showcases, there is an option to purchase either a 10 or 20 minute presentation, which will be pre-recorded in advance and available to all registered attendees before, during and after the conference on the event’s portal. There are also a limited number of 20-min Spotlight presentations with additional branding to provide even higher exposure, which will be broadcasted live during the main programme after relevant panel discussion and available on demand afterwards. Start-up companies, which are looking for seed financing may also apply for a 5 or 10 minute showcase option. The Sachs team can assist with the pre-recording of the presentation or you can upload a video you already have. Interested viewers will be able to message or request a meeting with you using the Online Meeting System.

EXHIBITING OPPORTUNITIES:

Make connections, engage in conversation, and exchange knowledge with key decision-makers eager to learn how your company can help them meet their goals and achieve their mission. Exhibiting at Sachs Spring Life Sciences Week is an effective way to gain leads, introduce new products and services, expand sales, and build relationships.
 
The virtual exhibition package includes a dedicated virtual page, where we can: upload your branded company’s profile and list ways to reach you; share video or images about services you provide; have files ready for download, if you wish to share any additional information with potential clients.

SPONSORING OPPORTUNITIES:

There are a limited number of sponsorship opportunities for the forum, which includes speaking, advertising and branding options. Sponsors typically include investment banks and funds, large pharma, technology companies and service providers, including Stock Exchanges, IR companies, CROs, international lawyers and consulting companies. Tailored packages are available upon request. You can view latest event’s sponsors here.

---

To learn more about presenting, exhibition or sponsorship opportunities, please contact us at [email protected] or by phone + 44 (0)203 463 4890.

SILVER SPONSORS:

BRONZE SPONSOR:

---

CONTRIBUTING SPONSORS:

---

​SUPPORTERS:

---

PARTICIPATING PHARMAS:

---

​FINANCIAL, ADVISORY, INVESTORS ATTENDING:

3B Future Health Fund (formerly Helsinn Investment Fund)
3B Future Health Ventures Sarl (Helsinn Investment Fund)
3E Bioventures
4BIO Capital
AbbVie Deutschland GmbH Co. KG
AbbVie Ventures
Abingworth LLP
ACXIT Capital Management GmbH
Additio Investment Group
Advent Life Sciences
aescuvest international GmbH
Aglaia Oncology Funds
Aisling Capital LLC
ALSA Ventures
Altitude Investment Management
Andera Partners
Aqua Partners LLC
ARCH Venture Partners
Arix Bioscience Plc.
ARTO AG
Asabys Partners
Asklepios Advisors
ATEM Capital LLC
Atlas Advisors LLC
AVANTECA Partners AG
Bergmann zur Hausen & Cie. GmbH
BERNINA BioInvest Ltd.
Bioqube Ventures
Bioscience Managers
Biotech Alliances International, Inc.
Biotechnology Business Institute
Bootstrap Europe
Boston Consulting Group
Bpifrance
Breslin AG
BRESLIN AG & LSFA
Bridge Valley Ventures LLP
Brightlands Venture Partners B.V.
Brock Capital Group LLC
Brothers & Partners Europe
Bryan, Garnier & Co. GmbH
Capricorn Partners NV
Cathay Capital
Cederberg GmbH
Claris Ventures
Clave Capital
Clavis Capital Ltd.
coparion GmbH & Co. KG
Crosswave Management, Inc.
CTI Life Sciences
Curam Capital Management LLP
DeBere Capital Partners
Debiopharm Innovation Fund S.A.
Digital Networks Plc. S.r.l.
Dorset Capital LLC
Eaton Square
EIT Health Investor Network
European Investment Fund
Ferghana Partners
Forbion
Forty51 Ventures
Fraser Finance LLP
Fund+
FutuRx Ltd.
GCF Family Office
Generation Life Science Fund
Genextra S.p.A.
Gilde Healthcare Partners
Gimv NV
Global Founders Capital GmbH
Global Investment Bridge AG
Global Neurohealth Ventures
GLSV GmbH
Good Health Capital LLC
GreenSky Capital
GrowthCube Partners LLC
Guoqian VC
Gurnet Point Capital
H.C. Wainwright
H.C. Wainwright & Co., LLC
Hadean Ventures AS
HBM Partners AG
Health Passion Fund
HealthCap
High-Tech Gründerfonds
Hillhouse Capital
Hovione Capital, Sociedade de Capital de Risco, SA
i&i Prague s r.o.
i2020 Accelerator

To View All - Click Here